Asset Details
Do you wish to reserve the book?
Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9
Do you wish to request the book?
Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Complement regulatory protein CD46 promotes bladder cancer metastasis through activation of MMP9
2024
Overview
CD46, a transmembrane protein known for protecting cells from complement-mediated damage, is frequently dysregulated in various types of cancer. Its overexpression in bladder cancers safeguards the cancer cells against both complement and antibody-mediated cytotoxicity. The present study explored a new role of CD46 in facilitating cancer cell invasion and metastasis, examining its regulatory effect on matrix metalloproteases (MMPs) and their effect on the metastatic capability of bladder cancer cells. Specifically, CD46 alteration positively influenced MMP9 expression, but not MMP2, in several bladder cancer cell lines. Furthermore, CD46 overexpression triggered phosphorylation of p38 MAPK and protein kinase B (AKT), leading to enhanced activator protein 1 (AP-1) activity via c-Jun upregulation. The inhibition of p38 or AKT pathways attenuated the CD46-induced MMP9 and AP-1 upregulation, indicating that the promotion of MMP9 by CD46 involved activating both p38 MAPK and AKT. Functionally, the upregulation of MMP9 by CD46 translated to increased migratory and invasive capabilities of bladder cancer cells, as well as enhanced in vivo metastasis. Overall, the present study revealed a novel role for CD46 as a metastasis promoter through MMP9 activation in bladder cancers and highlighted the regulatory mechanism of CD46-mediated MMP9 promotion via p38 MAPK and AKT activation.
